In the combination phase , adverse events that were reported at least @ % more frequently with olaparib plus chemotherapy than with chemotherapy alone were alopecia ( @ -LSB- @ % -RSB- of @ vs @ -LSB- @ % -RSB- of @ ) , nausea ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , neutropenia ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , diarrhoea ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , headache ( @ -LSB- @ % -RSB- vs seven -LSB- @ % -RSB- ) , peripheral neuropathy ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , and dyspepsia ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) ; most were of mild-to-moderate intensity .